Novo Holdings publishes its 2025 Seed Investments Annual Review and Business Update

• Over $750 million raised by portfolio companies

• Significant clinical milestones achieved by portfolio

• Novo Holdings Quantum Investments made its first investments

Seed Investments, the early-stage investment and company creation team of Novo Holdings, today publishes its review of 2025 – a year of supporting innovation for long-term growth.

With a continued focus on identifying, building and investing in early-stage life sciences companies grounded in strong science, the team made progress across its activities, including company formation, portfolio development and new strategic initiatives.

Read the full 2025 Annual Review here.

Søren Møller, Managing Partner at Seed Investments, said: “Over the past year, we have focused on strengthening our company creation platform and supporting portfolio companies through defined development milestones. Our priority remains to take a disciplined, long-term approach to building early-stage life sciences companies.”

Highlights from 2025 include:

• In 2024, Novo Holdings initiated Quantum Investments as a new strategic area, with committed capital to support the development of a quantum technology ecosystem. In 2025, Quantum Investments made its first investments.

• The de novo foundry was re-launched with renewed leadership and focus, alongside continued build-out of internal capabilities in areas such as project leadership, financing, CMC, and business development. These efforts are intended to support both new company formation and the progression of existing portfolio companies.

• During the year, Seed Investments completed several new therapeutic investments and participated in several follow-on financing rounds across the portfolio. Portfolio companies reported development and clinical milestones across multiple disease areas, reflecting ongoing operational progress.